These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 36599769)
1. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. Lobefaro R; Mariani L; Peverelli G; Ligorio F; Fucà G; Rametta A; Zattarin E; Leporati R; Presti D; Cantarelli B; Depretto C; Vingiani A; Manoukian S; Scaperrotta G; Bianchi GV; Capri G; Pruneri G; de Braud F; Vernieri C Clin Breast Cancer; 2023 Apr; 23(3):e151-e162. PubMed ID: 36599769 [TBL] [Abstract][Full Text] [Related]
2. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N Trials; 2015 Dec; 16():575. PubMed ID: 26673577 [TBL] [Abstract][Full Text] [Related]
3. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429 [TBL] [Abstract][Full Text] [Related]
4. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N; Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768 [TBL] [Abstract][Full Text] [Related]
6. [Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer]. Furuiye M; Ishiwata N; Jin Y; Miyashita Y; Takano S; Yoshizawa M; Miyake S; Inase N; Yoshizawa Y Gan To Kagaku Ryoho; 2008 Jul; 35(7):1133-8. PubMed ID: 18633251 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. Gluz O; Nitz U; Liedtke C; Christgen M; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Bangemann N; Lindner C; Kuemmel S; Clemens M; Potenberg J; Staib P; Kohls A; von Schumann R; Kates R; Kates R; Schumacher J; Wuerstlein R; Kreipe HH; Harbeck N J Natl Cancer Inst; 2018 Jun; 110(6):628-637. PubMed ID: 29228315 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study. Vasseur A; Carton M; Guiu S; Augereau P; Uwer L; Mouret-Reynier MA; Levy C; Eymard JC; Ferrero JM; Leheurteur M; Goncalves A; Robert M; De La Motte Rouge T; Bachelot T; Petit T; Debled M; Grinda T; Desmoulins I; Vanlemmens L; Nicolaï V; Simon G; Cabel L Breast; 2022 Oct; 65():136-144. PubMed ID: 35944353 [TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646 [TBL] [Abstract][Full Text] [Related]
10. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial. Ligorio F; Lobefaro R; Fucà G; Provenzano L; Zanenga L; Nasca V; Sposetti C; Salvadori G; Ficchì A; Franza A; Martinetti A; Sottotetti E; Formisano B; Depretto C; Scaperrotta G; Belfiore A; Vingiani A; Ferraris C; Pruneri G; de Braud F; Vernieri C Int J Cancer; 2024 Jan; 154(1):114-123. PubMed ID: 37615485 [TBL] [Abstract][Full Text] [Related]
11. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP J Clin Oncol; 2014 Dec; 32(34):3840-7. PubMed ID: 25349301 [TBL] [Abstract][Full Text] [Related]
12. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480 [TBL] [Abstract][Full Text] [Related]
13. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816 [TBL] [Abstract][Full Text] [Related]
14. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. Vernieri C; Prisciandaro M; Milano M; Cona MS; Maggi C; Brambilla M; Mennitto A; Fabbroni C; Farè E; Cresta S; Celio L; Mariani G; Bianchi G; Capri G; de Braud F Clin Breast Cancer; 2019 Apr; 19(2):e306-e318. PubMed ID: 30635175 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409 [TBL] [Abstract][Full Text] [Related]
16. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Alva A; Daignault S; Smith DC; Hussain M Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901 [TBL] [Abstract][Full Text] [Related]
18. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503 [TBL] [Abstract][Full Text] [Related]
19. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis. Wang H; Zhang N; Sun Q; Zhao Z; Pang H; Huang X; Zhang R; Kang W; Shan M J Cancer Res Clin Oncol; 2024 Jun; 150(6):291. PubMed ID: 38836955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]